US EditionExperts Hail Budget 2026 Health Push, Flag Biopharma, District-Level Care and Affordability as Game-Changers
The ₹10,000 crore scheme aims to build domestic biologics production and a clinical-trial network with over 1,000 accredited sites, addressing India's rising non-communicable disease burden.
- In the Union Budget 2026, Finance Minister Nirmala Sitharaman announced Biopharma SHAKTI to build domestic biologics capacity with a ₹10,000 crore five-year outlay.
- Responding to recent US tariff moves, India’s disease burden is shifting toward NCDs, with 63% of deaths caused by such diseases, per the United Nations report.
- The scheme will create a network of over 1,000 accredited clinical-trial sites and will launch three new NIPERs while upgrading seven institutes, strengthening the CDSCO.
- The move positions India’s pharmaceutical sector, supplying about 20% of global generics and exporting to 191 countries, to diversify exports amid tariff risks in highly regulated markets .
- To bolster care and training, the Budget aims to train 1.5 lakh caregivers next year and develop five Regional Medical Hubs in partnership with the private sector.
14 Articles
14 Articles
Budget Reinforces Long-term Biopharma Growth Despite No New Tax Incentives: EY
Get latest articles and stories on Business at LatestLY. The Union Budget 2026 has signalled a sustained policy push for India's pharmaceutical and life sciences sector, with a strong emphasis on biopharma innovation, research infrastructure and affordability, even as direct tax incentives remain unchanged, noted EY's Budget sectoral alert. Business News | Budget Reinforces Long-term Biopharma Growth Despite No New Tax Incentives: EY.
Experts hail Budget 2026 health push, flag biopharma, district-level care and affordability as game-changers
Union Budget 2026 boosts health spending above ₹1 lakh crore, launches the ₹10,000-crore Biopharma Shakti initiative, expands trauma centres and regional medical hubs and prioritises research, workforce training and medical tourism — winning praise from doctors and industry experts.
A comprehensive strategy is being developed to expand biopharmaceutical manufacturing in India, incorporating health reform and innovation. The primary goal is to provide affordable medicines for non-communicable diseases such as cancer, diabetes, and autoimmune disorders. A plan worth ₹10,000 crore will expand the biologics sector over the next ten years. Three national institutes will be established for pharmaceutical education and research.
Budget 2026: In Budget 2026, Finance Minister Nirmala Sitharaman announced a massive fund of ₹10,000 crore under the "Biopharma Shakti" scheme. Following this announcement, Biocon shares saw a strong rise of up to 3%. Several other stocks, including Sun Pharma and Piramal Pharma, also surged during trading.
Coverage Details
Bias Distribution
- 66% of the sources lean Right
Factuality
To view factuality data please Upgrade to Premium
